Eos
VC Fund
Edinburgh, United Kingdom
Eos is a VC fund in Edinburgh focused on Biotechnology and Health Care. Eos Advisory is focused on providing seed funding to ventures based upon strong and innovative science, technology and engineering.
- Total investments:
- 43
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Eos invests in
Stages Eos invests in
Countries Eos invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.5M–$11M
- Series A
- $1.6M–$47M
Investment Focus
Industry
- Biotechnology 11 (26%)
- Health Care 5 (12%)
- Medical 4 (9%)
- Manufacturing 4 (9%)
- Therapeutics 3 (7%)
Stage
- Seed 18 (42%)
- Series A 5 (12%)
- Funding Round 4 (9%)
- Series B 2 (5%)
- Venture - Series Unknown 2 (5%)
Country
- United Kingdom 20 (47%)
- Ireland 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anne Muir
Director of Portfolio
|
Director of Portfolio | Total investments: 1 | Find email | |
Kevin Grainger
Founder and Chairman
|
Founder and Chairman | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| TaiSan is Battery Materials company, innovated proprietary quasi-solid gel polymer electrolyte and sodium-potassium metal anode to enable quasi-solid-state sodium battery. It leads to best-in-class energy density. We work with battery and automotive OEMs to scale our technology and signed 19 non-binding MoUs. | $6.2M / Seed / Jul 06, 2026 | ||
| Scarlet Therapeutics is developing the novel red blood cell-based therapeutics (tRBCs) generation platform. | $4.4M / Seed / May 07, 2026 | ||
| Bioliberty are a medtech start-up developing rehabilitation solutions for degenerative and traumatic conditions. | $8.3M / Series A / Mar 18, 2026 | ||
| Neupulse is the brand of Neurotherapeutics LtdThe direction of our current research was very much shaped by the feedback we received from individuals with tic disorders and their families.When we asked them for their thoughts on our research priorities we were frequently told that what was really needed was a safe and effective non-drugtreatment for tic disorder that could be used outside of the clinic and gave individuals control over their tics. This led directly to us focusing on the use of peripheral nerve stimulation as a means of bringing about changes in the brain networks associated with the production of tics. We demonstrated that delivering rhythmic patterns of mild electrical stimulation to the median nerve at the wrist could be used to increase the power and the synchronicity of the brain oscillations (rhythms) associated with the suppression of movements, and that this type of stimulation was sufficient to dramatically reduce the frequency of tics and remove the urge-to-tic in individuals with tic disorders.Importantly, we also showed that this type of stimulation did not materially affect the execution of volitional (intentional) movements or impair cognitive functions such as attention. | $4.1M / Seed / Feb 12, 2026 | ||
| Nami Surgical provides robotic surgery technology solutions to enhance patient care while giving surgeons intuitive, high-performance moveable instruments. | $2.6M / Jan 28, 2026 | ||
| Digitising Chemistry and Chemical Discovery | $50M / Series B / Oct 21, 2025 | ||
| EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $6.1M / Seed / Aug 28, 2025 | ||
| Laverock Therapeutics is a biotechnology company developing programmable gene control technologies for advanced cell and gene therapies. The company builds a platform that uses endogenous microRNA and gene regulatory mechanisms to enable precise, tunable control of gene expression, allowing engineered cells to activate or silence therapeuticfunctions in response to specific biological signals. Its core approach focuses on “disease-responsive” therapies, where engineered cells are designed to sense the surrounding cellular environment and adjust their activity accordingly. This enables therapies that can switch on or off, or modulate activity levels, depending on disease state or tissue context, rather than operating in a constant active mode. The company’s platform supports multiplex gene control, meaning multiple genes can be regulated simultaneously within engineered cells. This capability is applied to developing next-generation cell therapies such as CAR-T cells and macrophages for oncology, as well as exploratory programs in genetic, inflammatory, and metabolic diseases. | Seed / Jun 30, 2025 | ||
| Dxcover is a clinical-stage liquid biopsy firm that is developing diagnostics for the early diagnosis of numerous malignancies, when treatment has a better possibility of having an influence on outcomes. The business was the first to use infrared spectroscopy of circulating pan-omic indicators to detect and identify cancer. The business hasgenerated compelling clinical data on the diagnosis of Stage I and Stage II malignancies with high accuracy.Dxcover was established in 2016 in Glasgow, Glasgow City by David S Palmer, Holly Butler, and Matthew Baker. | $6.2M / Feb 03, 2025 | ||
| Concinnity Genetics transforms the safety of gene therapies by designing novel control mechanisms using an AI platform. | $3.8M / Seed / Dec 16, 2024 | ||
| See all 43 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Eos invest in?
Eos invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 43 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Eos's check size?
Eos typically joins rounds of $1.5M–$11M at Seed and $1.6M–$47M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Eos participates in.
How do I contact Eos?
Public channels for Eos include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Eos?
The team at Eos includes Anne Muir (Director of Portfolio) and Kevin Grainger (Founder and Chairman). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
